

D2  
43. (Amended) A process for the production of a biologically active VEGF-like protein comprising expressing a nucleic acid molecule encoding a polypeptide comprising SEQ ID NO:6 in a host and isolating said VEGF-like protein.

44. (Amended) The method according to Claim 43 wherein said nucleic acid comprises SEQ ID NO:5 or hybridizes under low stringency conditions to a nucleic acid comprising SEQ ID NO:5.

**Please add the following new claim:**

D3  
45. (New) The method according to Claim 44 wherein said low stringency conditions comprise 4-6x SSC/0.1-0.5% w/v SDS at 37°C to 45°C for 2 to 3 hours.

**REMARKS**

add E29  
Applicants have amended Claims 26, 43 and 44. Support for the amendment to Claim 26 is found throughout the specification and particularly at Page 5, Lines 15-21. Support for the amendment to Claims 43 and 44 is found throughout the specification and particularly at Page 7, Lines 9-10 and Page 28, Lines 2-8, for example. No new matter has been added. Claim 45 has been added to further define the subject matter to which applicants are entitled. Support for Claim 45 is found at Page 7, Lines 9-10. No new matter has been added.

The Examiner has requested the cancellation of the original sequence listing filed on September 8, 2000. Applicants observe that a substitute sequence listing dated December 12, 2000 included a separate amendment pursuant to 37 C.F.R. §1.825 and 1.111